NCT00402181View on ClinicalTrials.gov

An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

Siltuximab

Siltuximab 6 mg/kg as intravenous infusion once every 2 weeks for 12 cycles and duration of each cycle is 28 days.

DRUG

Dexamethasone

Dexamethasone 40 mg tablet orally on Day 1 to 4, 9 to 12 and 17 to 20 for maximum 4 cycles after that on Day 1 to 4 up to 12 cycles and duration of each cycle is 28 days.

Trial Locations (13)

Unknown

Duarte

Norwalk

Indianapolis

Rochester

New York

Chapel Hill

Pittsburgh

North Charleston

Houston

Amsterdam

Leiden

Rotterdam

The Hague

Sponsors

Lead Sponsor

Centocor, Inc.
All Listed Sponsors
lead

Centocor, Inc.

INDUSTRY